Dose optimization of an adjuvanted peptide-based personalized neoantigen melanoma vaccine
PLOS Computational Biology · 2024
DOI: 10.1371/journal.pcbi.1011247 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Computational Biology, 2024. Verfasst von Wencel Valega-Mackenzie und 5 weiteren Autor:innen. Beteiligte Einrichtung: Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryla…. Hauptthemen laut MEDLINE: Melanoma, Cancer Vaccines. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: Oak Ridge Institute for Science and Education.
Abstract (Originalsprache)
The advancements in next-generation sequencing have made it possible to effectively detect somatic mutations, which has led to the development of personalized neoantigen cancer vaccines that are tailored to the unique variants found in a patient’s cancer. These vaccines can provide significant clinical benefit by leveraging the patient’s immune response to eliminate malignant cells. However, determining the optimal vaccine dose for each patient is a challenge due to the heterogeneity of tumors. To address this challenge, we formulate a mathematical dose optimization problem based on a previous mathematical model that encompasses the immune response cascade produced by the vaccine in a patient. We propose an optimization approach to identify the optimal personalized vaccine doses, considering a fixed vaccination schedule, while simultaneously minimizing the overall number of tumor and activated T cells. To validate our approach, we perform in silico experiments on six real-world clinical trial patients with advanced melanoma. We compare the results of applying an optimal vaccine dose to those of a suboptimal dose (the dose used in the clinical trial and its deviations). Our simulations reveal that an optimal vaccine regimen of higher initial doses and lower final doses may lead to a reduction in tumor size for certain patients. Our mathematical dose optimization offers a promising approach to determining an optimal vaccine dose for each patient and improving clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, United States of America.
- Office of Therapeutic Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, United States of America.
ORCID-Profile: Wencel Valega-Mackenzie, Marisabel Rodriguez Messan, Osman N Yogurtcu, Hong Yang
Förderung
- Oak Ridge Institute for Science and Education
Zitieren
APA
Valega-Mackenzie, W., Rodriguez Messan, M., Yogurtcu, O. N., Nukala, U., Sauna, Z. E., & Yang, H. (2024). Dose optimization of an adjuvanted peptide-based personalized neoantigen melanoma vaccine. PLOS Computational Biology. https://doi.org/10.1371/journal.pcbi.1011247
Vancouver
Valega-Mackenzie W, Rodriguez Messan M, Yogurtcu ON, Nukala U, Sauna ZE, Yang H. Dose optimization of an adjuvanted peptide-based personalized neoantigen melanoma vaccine. PLOS Computational Biology. 2024. doi:10.1371/journal.pcbi.1011247
BibTeX
@article{ValegaMackenzie2024,
author = {Valega-Mackenzie, Wencel and Rodriguez Messan, Marisabel and Yogurtcu, Osman N and Nukala, Ujwani and Sauna, Zuben E and Yang, Hong},
title = {Dose optimization of an adjuvanted peptide-based personalized neoantigen melanoma vaccine},
journal = {PLOS Computational Biology},
year = {2024},
doi = {10.1371/journal.pcbi.1011247}
}
EUVIMED